.jpeg.jpg "Khalifa Alrajeh, PharmD photo")
PhD Student
Virginia Commonwealth University
Khalifa Alrajeh is currently a Ph.D. student at Virginia Commonwealth University College of Pharmacy in the Department of Pharmacotherapy and Outcome Sciences. He earned his PharmD from King Faisal University in Saudi Arabia. Then, he completed a two-year Advanced Pharmacy Practice and a Master of Science in Clinical Research from the Medical University of South Carolina. He currently studies cardiovascular genomics and pharmacogenomics in minority populations and serves as a research coordinator and research assistant in the Filipino American Heart Health Study. He published original several research articles. The first article focused on the genetic assessment of gout and hyperuricemia in disproportionate populations, including Filipino. The second article published highlighted the role of pharmacogenetic testing in gout management (review article). The third research article studied the prevelance of the very important drug-metabolizing pharmacogene (CYP2C19) in Asian, Native Hawaiian, and Pacific Islander populations. The fourth article was a special report on highlighting the importance of pharmacogenetic testing for the clinically relevant drug-transporting pharmacogene (ABCG2) prior to prescribing rosuvastatin to individuals from Asian ancestry as they have signifcantly high prvelance of the reduced function ABCG2, relative to non-Asians, making them more likely to have adverse reactions. He served as an author who contributed to developing methodology, software, data curation, and writing-initial draft of the first article and served as the first author in the second, third and fourth published articles. He has been a member of ASCPT since 2021.